BR112018007590A2 - método para produzir proteína de fusão que tem domínio fc de igg - Google Patents

método para produzir proteína de fusão que tem domínio fc de igg

Info

Publication number
BR112018007590A2
BR112018007590A2 BR112018007590-6A BR112018007590A BR112018007590A2 BR 112018007590 A2 BR112018007590 A2 BR 112018007590A2 BR 112018007590 A BR112018007590 A BR 112018007590A BR 112018007590 A2 BR112018007590 A2 BR 112018007590A2
Authority
BR
Brazil
Prior art keywords
fusion protein
igg
domain
produce fusion
preparing
Prior art date
Application number
BR112018007590-6A
Other languages
English (en)
Inventor
Jae Park Soon
Shin Chung Hye
Ah You Sun
Soo Cho Jeong
Original Assignee
Alteogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58703642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018007590(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alteogen, Inc. filed Critical Alteogen, Inc.
Priority claimed from PCT/KR2016/011561 external-priority patent/WO2017065559A1/ko
Publication of BR112018007590A2 publication Critical patent/BR112018007590A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

a presente invenção refere-se a um método para preparar uma proteína de fusão que tem um domínio fc de igg e, especificamente, a um método para preparar uma proteína de fusão que tem um domínio fc de igg, sendo que o método compreende adicionalmente uma etapa de cultivar células que produzem a proteína de fusão a uma temperatura de cultura diminuída, o que aumenta, assim, o crescimento celular e a viabilidade celular de modo a aumentar a produtividade de proteína de fusão e inibir a geração de agregado de modo a aprimorar a qualidade e o rendimento de produção.
BR112018007590-6A 2015-10-15 2016-10-14 método para produzir proteína de fusão que tem domínio fc de igg BR112018007590A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2015-0144330 2015-10-15
KR20150144330 2015-10-15
KR1020160132633A KR101936049B1 (ko) 2015-10-15 2016-10-13 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
KR10-2016-0132633 2016-10-13
PCT/KR2016/011561 WO2017065559A1 (ko) 2015-10-15 2016-10-14 Igg fc 도메인을 가지는 융합 단백질의 생산방법

Publications (1)

Publication Number Publication Date
BR112018007590A2 true BR112018007590A2 (pt) 2018-10-23

Family

ID=58703642

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007590-6A BR112018007590A2 (pt) 2015-10-15 2016-10-14 método para produzir proteína de fusão que tem domínio fc de igg

Country Status (12)

Country Link
US (2) US11414476B2 (pt)
EP (2) EP4098659A1 (pt)
JP (2) JP6783305B2 (pt)
KR (1) KR101936049B1 (pt)
CN (2) CN115247196A (pt)
AU (1) AU2016339642B2 (pt)
BR (1) BR112018007590A2 (pt)
CA (1) CA3001977C (pt)
ES (1) ES2945537T3 (pt)
MX (1) MX2018004580A (pt)
PL (1) PL3363811T3 (pt)
RU (1) RU2732237C2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2018194413A1 (en) 2017-04-21 2018-10-25 Yuhan Corporation Method for producing dual function proteins and its derivatives
CN115197961B (zh) * 2022-06-20 2024-04-16 岭南现代农业科学与技术广东省实验室肇庆分中心 一种非洲猪瘟病毒b602l重组蛋白稳定表达细胞系及其构建方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
NZ515913A (en) 1999-06-08 2004-01-30 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US20030064053A1 (en) * 2001-08-31 2003-04-03 Shengjiang Liu Multivalent protein conjugate with multiple ligand-binding domains of receptors
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
JP2012525415A (ja) 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
CA2795461C (en) * 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
WO2014020160A1 (en) 2012-08-02 2014-02-06 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
JP6689189B2 (ja) 2013-03-26 2020-04-28 コヒラス・バイオサイエンシズ・インコーポレイテッド タンパク質産生方法
RU2639660C2 (ru) 2013-04-15 2017-12-21 Телефонактиеболагет Л М Эрикссон (Пабл) Сигнализация системной информации к мтс-устройствам
CN103319610B (zh) 2013-07-05 2016-01-27 华博生物医药技术（上海）有限公司 重组融合蛋白及其制法和用途
KR102410393B1 (ko) 2014-01-29 2022-06-16 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
CN104974262B (zh) * 2014-04-04 2019-08-09 华博生物医药技术（上海）有限公司 重组双功能融合蛋白及其制法和用途
RU2016152693A (ru) 2014-06-03 2018-07-09 Люпин Лимитед Способ культивирования клеток для получения белка
KR20160132633A (ko) 2015-05-11 2016-11-21 주식회사 엘지화학 배터리 시스템 및 그 연결 제어 방법
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TW202140776A (zh) 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基

Also Published As

Publication number Publication date
CN115247196A (zh) 2022-10-28
RU2018117705A3 (pt) 2019-11-15
EP3363811A4 (en) 2019-03-13
US20220348636A1 (en) 2022-11-03
RU2732237C2 (ru) 2020-09-14
PL3363811T3 (pl) 2023-07-17
ES2945537T3 (es) 2023-07-04
JP6783305B2 (ja) 2020-11-11
KR20170044594A (ko) 2017-04-25
AU2016339642A1 (en) 2018-04-12
EP3363811A1 (en) 2018-08-22
RU2018117705A (ru) 2019-11-15
KR101936049B1 (ko) 2019-01-08
CA3001977A1 (en) 2017-04-20
US11414476B2 (en) 2022-08-16
MX2018004580A (es) 2018-09-19
CA3001977C (en) 2023-06-20
CN108137672B (zh) 2022-09-06
JP2020114266A (ja) 2020-07-30
CN108137672A (zh) 2018-06-08
JP2018530344A (ja) 2018-10-18
EP3363811B1 (en) 2023-04-19
EP4098659A1 (en) 2022-12-07
AU2016339642B2 (en) 2019-07-25
US20180298078A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
BR112018007590A2 (pt) método para produzir proteína de fusão que tem domínio fc de igg
BR112018002214A2 (pt) ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho?
BR112017007770A2 (pt) cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
BR112018008648A2 (pt) métodos de geração de células t a partir de células tronco e métodos imunoterapêuticos ao usar células t
WO2017051347A3 (en) Cells and method of cell culture
PH12014501407A1 (en) Plant artificial seeds and methods for the production thereof
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
BR112016027290A2 (pt) métodos para a produção de ramnolipídeos".
NZ611862A (en) Animal cell culturing method
EA202091407A1 (ru) Состав бессывороточной среды для культивирования клеток и способы его применения
MX2016010236A (es) Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
MX363690B (es) Expansión de celulas madre adultas in vitro.
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
BR112018075548A2 (pt) método para estabilizar proteínas
BR112017023624A2 (pt) método de cultivo em pequena escala para células em suspensão
AR097805A1 (es) Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados
MX2020001357A (es) Produccion microbiana de aminas grasas.
EP3511410A4 (en) MEDIUM FOR THE CULTURE OF STEM CELLS, METHOD FOR THE CULTURE OF STEM CELLS, STEM CELL GROWTH PROMOTER AND COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
AR104050A1 (es) Proceso de producción con iones de cobre controlados
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]